These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11184046)

  • 21. Preadmission strategies: reducing the length of preoperative stay.
    Graham K; Morash R; Kitts JB
    Leadersh Health Serv; 1996; 5(1):7-11. PubMed ID: 10154229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare marketing--using HIS resources.
    Wagner JR
    Comput Healthc; 1987 Jun; 8(6):53-5. PubMed ID: 10282094
    [No Abstract]   [Full Text] [Related]  

  • 25. The Joint Commission complex organization survey process and its impact on hospital-based home care and hospice providers.
    Friedman MM
    Home Healthc Nurse; 2004 Dec; 22(12):854-7. PubMed ID: 15597008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease.
    Katz PO; Tutuian R
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):371-84. PubMed ID: 11403533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Feb; 62(2):26-34. PubMed ID: 17291140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Choreographing OA conversion--a task to keep you on your toes.
    Dyer NR; Wagner JR
    Comput Healthc; 1986 Sep; 7(9):22-6. PubMed ID: 10277452
    [No Abstract]   [Full Text] [Related]  

  • 31. Developing and financing a palliative care program.
    Edens PS; Harvey CD; Gilden KM
    Am J Hosp Palliat Care; 2008; 25(5):379-84. PubMed ID: 18539765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.
    Russo P; Brutti C
    Clin Ther; 2007 Apr; 29(4):751-8. PubMed ID: 17617299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing the rules. With hospitals increasingly dissatisfied with the accreditation process and its high costs, the JCAHO overhauls its approach.
    Morrissey J
    Mod Healthc; 2002 Oct; 32(40):8-9, 16, 3. PubMed ID: 12389315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Learning from defects to enhance morbidity and mortality conferences.
    Berenholtz SM; Hartsell TL; Pronovost PJ
    Am J Med Qual; 2009; 24(3):192-5. PubMed ID: 19258468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical redesign using all patient refined diagnosis related groups.
    Sedman AB; Bahl V; Bunting E; Bandy K; Jones S; Nasr SZ; Schulz K; Campbell DA
    Pediatrics; 2004 Oct; 114(4):965-9. PubMed ID: 15466092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The new JCAHO pain standards: implications for pain management nurses.
    Berry PH; Dahl JL
    Pain Manag Nurs; 2000 Mar; 1(1):3-12. PubMed ID: 11706454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.